Extended regimens of the vaginal contraceptive ring: cycle control

Guazzelli, Cristina Aparecida Falbo; Barreiros, F.; Barbosa, Ricardo Luís; Araújo, Fábio Fernando de; Moron, Antônio Fernandes

doi:10.1016/j.contraception.2009.05.004

Cited by 34 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Guazzelli y cols (12), reportan un estudio comparativo entre el anillo vaginal con liberación de 120 ug de etonogestrel y 15 ug de EE/ día y la forma oral de 30 ug de EE + 150 ug de desogestrel usados ambos en ciclo extendido de 84 días con 7 días de descanso por el periodo de 1 año. Los días de sangrado o goteo menstrual disminuyen significativamente con ambos componentes, siendo esta reducción significativamente menor en el grupo oral; durante este periodo hay una significativa reducción con ambos productos en el goteo o sangrado intermenstrual siendo esta significativamente menor en las usuarias del anillo vaginal.…”

Section: Discussionunclassified

“…El 60% de las mujeres italianas prefieren tener sangrados menos de una vez al mes, no necesariamente por razones médicas, sino por conveniencias prácticas, lo cual concuerda con datos provenientes de otros países europeos (5). Respondiendo a la creciente aceptabilidad por parte de determinadas usuarias de este uso extendido de AOC siguen apareciendo publicaciones con el uso de esta forma de anticoncepción, usando ya sea distintas fórmulas hormonales combinadas orales, considerando aspectos tanto clínicos (6,7,8,9) como variaciones metabólicas (10,11) o en la forma de anillos vaginales (12,13).…”

Section: Introductionunclassified

See 1 more Smart Citation

Experiencia piloto con el uso extendido de un anticonceptivo oral combinado de baja dosis de estrógeno

2011

Rev. chil. obstet. ginecol.

View full text Add to dashboard Cite

RESUMENObjetivo: Evaluar en una experiencia piloto la aceptabilidad y bienestar de la usuaria, después de un periodo de 12 meses de un anticonceptivo hormonal combinado oral de baja dosis estrogénica, con modalidad de uso extendido de 84 píldoras activas consecutivas, seguidas de 7 días de placebo. Método: Se incorporan 25 mujeres voluntarias que usan una combinación de 20 ug de etinilestradiol + 3 mg de drospirenona, con un tiempo de uso de 12 meses. En calendario de registro diario se consignan los días de sangrado o goteo genital así como todo tipo de fármaco ingerido. Al término de los 12 meses se efectúa una encuesta respecto al grado de satisfacción con la posología recibida. Resultados: 13 usuarias (52%) cumplen los 12 meses de uso. Todas ellas manifiestan un alto grado de conformidad, destacando las ventajas de presentar periodos menstruales ocasionales, mejoría marcada en la sintomatología compatible con el síndrome de tensión premenstrual con el consiguiente incremento del bienestar general. Siete usuarias (28%) no terminan el estudio por razones médicas, siendo 6 de estas por alteraciones de los flujos rojos y en 5 casos (20%) se producen retiros no médicos. Conclusión: Esta experiencia, que es la primera con la formulación descrita, confirma en un porcentaje de usuarias las bondades adicionales reportadas en las experiencias previas con otros productos similares, respecto al uso extendido de anticoncepción hormonal oral en un grupo de mujeres que deseaban espaciar sus periodos menstruales.PALABRAS CLAVE: Anticoncepción hormonal de uso extendido, drospirenona, síndrome tensión premenstrual SUMMARYObjetives: A pilot study designed in order to know about the acceptability of an oral combined contraceptive pill, with low estrogen dose used in an extended way of 84 consecutive days, followed by 7 days of no pills ingestion during a scheduled follow up of 1 year. Methods: 25 volunteers women were recruited among those which wants to use oral combined contraceptive pills and who accepted this extended way of use. Combined contraceptive pills contains each 20 ug of ethinylestradiol plus 3 mg of drosperinone. At admission women were provided with menstrual diary cards in order to check all bleeding days plus any extra pharmaceutical compound received. At the end of the 12 months follow up an interview was done in order to know women experiences and acceptability of this extended way of use. Results: 52% of women end the study at the scheduled 12 months use. All of them feel that the main advantages of these extended way of use were to have few menstrual periods and improving premenstrual symtomatology with better quality of life. 7 women (28%) did not finish the study because of medical reasons being due in 6 of these for bleeding disturbances. Conclusions: This report is pioneer with the use this hormone combination in this extended

show abstract

Section: Discussionunclassified

Section: Introductionunclassified

Experiencia piloto con el uso extendido de un anticonceptivo oral combinado de baja dosis de estrógeno

2011

Rev. chil. obstet. ginecol.

View full text Add to dashboard Cite

show abstract

“…This contraceptive releases 120 µg of etonogestrel and 15 µg of EE/day and is currently approved for use over a 3-week period after which the ring is removed for 1 week, when the user will experience uterine bleeding. An extended regimen of use has been described, with good acceptability and good cycle control; however, this use is currently offlabel [22,23]. Reports suggest that the main reason for women to switch from other contraceptive methods to the CVR (47%) is that this device represents a new, attractive contraceptive method and that, furthermore, > 90% of users were shown to be satisfied with the ring [24].…”

Section: Existing Treatmentmentioning

confidence: 94%

Emerging female contraceptives

Bahamondes

Fernandes

et al. 2011

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

show abstract

“…This extended-cycle use of vaginal rings changed every 28 days without interruption for 49, 91 or 364 days demonstrated that unscheduled bleeding rates decreased rapidly over time, but spotting (vaginal blood loss that require the use of more than a panty liner) rates increased with longer term extended use [104].…”

Section: Recent Developments In Reduction Of Side Effects and Complicmentioning

confidence: 96%

New frontiers in female contraception (and male condoms): 2012

Nelson

2012

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

The goal of being planned and prepared for pregnancies is still only an abstract concept. Significant barriers to success from traditional sources (ambivalence, cultural and societal beliefs, the status of women, poverty) persist and are now joined by many other emerging structural problems. The consolidation of pharmaceutical companies reduces competition. The loss of profitability for contraceptives due to short-lasting patents, growing demand for generics and growing challenges from product liability reduce incentives for innovation. Healthcare reform in the US may further discourage new product development. However, new advances may still be possible from small start-up companies, philanthropic foundations and governmental research efforts. Other advances may be made by providing contraception in innovative ways and in the techniques we use to motivate patients to be more successful contraceptors.

show abstract

Extended regimens of the vaginal contraceptive ring: cycle control

Cited by 34 publications

References 11 publications

Experiencia piloto con el uso extendido de un anticonceptivo oral combinado de baja dosis de estrógeno

Experiencia piloto con el uso extendido de un anticonceptivo oral combinado de baja dosis de estrógeno

Emerging female contraceptives

New frontiers in female contraception (and male condoms): 2012

Contact Info

Product

Resources

About